These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 37060459

  • 1. Population plasma and urine pharmacokinetics and the probability of target attainment of fosfomycin in healthy male volunteers.
    Edwina AE, Koch BCP, Muller AE, Al Jalali V, Matzneller P, Zeitlinger M, Sassen SDT.
    Eur J Clin Pharmacol; 2023 Jun; 79(6):775-787. PubMed ID: 37060459
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
    Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC.
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin.
    Rodríguez-Gascón A, Canut-Blasco A.
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):19-24. PubMed ID: 31131588
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J, Xiong W, Chen Y, Zhao Y, Lu Y, Zhao D, Li W, Liu Y, Chen X.
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM, Trang M, Griffith DC, Lomovskaya O, Hammel JP, Loutit JS, Cammarata SK, Dudley MN, Ambrose PG, Rubino CM.
    Antimicrob Agents Chemother; 2022 Dec 20; 66(12):e0213021. PubMed ID: 36374023
    [Abstract] [Full Text] [Related]

  • 9. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J.
    Int J Antimicrob Agents; 2010 Feb 20; 35(2):156-63. PubMed ID: 20018492
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.
    Wangchinda W, Pogue JM, Thamlikitkul V, Leelawattanachai P, Koomanachai P, Pai MP.
    J Antimicrob Chemother; 2024 Jun 03; 79(6):1372-1379. PubMed ID: 38597137
    [Abstract] [Full Text] [Related]

  • 11. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
    Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP.
    J Clin Pharmacol; 2003 Oct 03; 43(10):1116-23. PubMed ID: 14517194
    [Abstract] [Full Text] [Related]

  • 12. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
    Lewis SJ, Mueller BA.
    J Clin Pharmacol; 2021 Feb 03; 61(2):211-223. PubMed ID: 32851685
    [Abstract] [Full Text] [Related]

  • 13. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW, Punt N, Vinks AA.
    Clin Ther; 2005 Jun 03; 27(6):762-72. PubMed ID: 16117983
    [Abstract] [Full Text] [Related]

  • 14. Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers.
    Al Jalali V, Matzneller P, Wulkersdorfer B, Chou S, Bahmany S, Koch BCP, Zeitlinger M.
    Antimicrob Agents Chemother; 2020 Dec 16; 65(1):. PubMed ID: 33106259
    [Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V, Docobo-Pérez F, Sojo J, Morales I, Lupión C, Martín D, Cameán M, Hope W, Pascual Á, Rodríguez-Baño J.
    Clin Microbiol Infect; 2018 Nov 16; 24(11):1177-1183. PubMed ID: 29649596
    [Abstract] [Full Text] [Related]

  • 16. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A, Juvany Roig R, Leiva Badosa E, Sabater Riera J, Pérez Fernández XL, Cárdenas Campos P, Rigo Bonin R, Alía Ramos P, Tubau Quintano F, Sospedra Martinez E, Colom Codina H.
    J Antimicrob Chemother; 2019 Oct 01; 74(10):2979-2983. PubMed ID: 31335959
    [Abstract] [Full Text] [Related]

  • 17. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K, Nakashima A, Morikawa N, Ikeda K, Murakami Y, Ohge H, Derendorf H, Sueda T.
    Antimicrob Agents Chemother; 2011 Dec 01; 55(12):5609-15. PubMed ID: 21947393
    [Abstract] [Full Text] [Related]

  • 18. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J.
    J Antimicrob Chemother; 2010 Aug 01; 65(8):1771-8. PubMed ID: 20530507
    [Abstract] [Full Text] [Related]

  • 19. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D, Simon P, Schmitt L, Petroff D, Dorn C, Dietrich A, Zeitlinger M, Huisinga W, Michelet R, Wrigge H, Kloft C.
    Clin Pharmacokinet; 2022 May 01; 61(5):655-672. PubMed ID: 34894344
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.